image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

Scapa

June 2018

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • SCPA
  • Price:
  • 403p
Scapa had a positive year end update with health care revenues growing 3.8%, including second half sales growth of 6.8% despite currency headwinds. Margins are expected to be above 15% reflecting investment in integrating two technology transfers.The industrial division has further delivered on its asset optimisation strategy with the Asian restructuring helping drive up margins. Healthy cash flow ensured net debt was just £3.8m after spending nearly £21m on acquisitions.Earlier Scapa announced another acquisition of BioMed for an initial US$13m, with another US$13m conditional on future performance. BioMed, based in Dallas, Texas, is a leading manufacturer of gels, creams, lotions, liquids and powders in the woun ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Related Articles

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X